See more : Remsense Technologies Limited (REM.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Replimune Group, Inc. (REPL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Replimune Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- RSC International Limited (RSCINT.BO) Income Statement Analysis – Financial Results
- Raysum Co., Ltd. (8890.T) Income Statement Analysis – Financial Results
- Bonheur ASA (BNHUF) Income Statement Analysis – Financial Results
- CSD Water Service Co., Ltd. (603903.SS) Income Statement Analysis – Financial Results
- ASARFI HOSPITAL LIMITED (ASARFI.BO) Income Statement Analysis – Financial Results
Replimune Group, Inc. (REPL)
About Replimune Group, Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.66M | 2.45M | 4.58M | 4.14M | 1.81M | 148.00K | 109.00K | 122.00K |
| Gross Profit | -2.66M | -2.45M | -4.58M | -4.14M | -1.81M | -148.00K | -109.00K | -122.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 174.96M | 126.53M | 79.55M | 56.75M | 38.76M | 22.17M | 13.52M | 6.94M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 23.20M | 17.44M | 8.77M | 5.71M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.81M | 50.55M | 38.77M | 23.20M | 17.44M | 8.77M | 5.71M | 2.71M |
| Other Expenses | 0.00 | -5.68M | -1.06M | -665.00K | -16.00K | 451.00K | -2.06M | 626.00K |
| Operating Expenses | 234.77M | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M | 16.96M | 8.21M |
| Cost & Expenses | 234.77M | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M | 16.96M | 8.21M |
| Interest Income | 16.70M | 10.01M | 390.00K | 916.00K | 2.42M | 2.59M | 288.00K | 25.00K |
| Interest Expense | 0.00 | 4.16M | 2.22M | 3.06M | 1.92M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.66M | 2.45M | 4.58M | 4.14M | 1.81M | 148.00K | 109.00K | 122.00K |
| EBITDA | -230.20M | -170.30M | -114.41M | -76.48M | -52.60M | -28.27M | -16.85M | -8.08M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -234.77M | -177.08M | -118.31M | -79.96M | -56.20M | -30.95M | -19.23M | -9.65M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.39M | 3.08M | 278.00K | -915.00K | 3.57M | 112.00K | -473.00K | 1.94M |
| Income Before Tax | -215.39M | -174.00M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 408.00K | 288.00K | 1.16M | 2.40M | 1.90M | 451.00K | -2.06M | 125.00K |
| Net Income | -215.79M | -174.28M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -0.64 | -0.36 |
| EPS Diluted | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -0.64 | -0.25 |
| Weighted Avg Shares Out | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 30.84M | 21.51M |
| Weighted Avg Shares Out (Dil) | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 30.84M | 30.84M |
Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)
NAARDEN, The Netherlands & MUNICH--(BUSINESS WIRE)--Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I (“Forbion Growth I") at the hard cap amount of EUR 360 million (USD 428...
Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting
Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2
India Medium Voltage Cable Accessories Market (2020 to 2027) - by Product Type, Technology and Industry Vertical - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "India Medium Voltage Cable Accessories Market by Product Type, Technology and Industry Vertical, Construction and Infrastructure: Global Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering. India medium voltage cable accessories market was valued...
Replimune to Present at the American Association for Cancer Research Annual Meeting 2021
WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual...
Replimune to Present at Three Upcoming Investor Conferences
WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will present and host one-on-one meetings...
Accenture Acquires REPL to Expand Retail Technology and Supply Chain Capabilities
LONDON--(BUSINESS WIRE)--Accenture (NYSE: ACN) has acquired REPL Group (“REPL”), a U.K.-based technology consultancy specializing in solutions for supply chain, workforce management, store operations and retail customer experiences. Terms of the acquisition were not disclosed. The acquisition expands Accenture’s capabilities that...
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all studies
ZielBio Appoints Dieter Weinand Executive Chair as Company Heads Toward the Clinic with Lead Oncology Therapeutic
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--ZielBio, Inc., an early-stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative drug discovery platform, has appointed industry veteran Dieter Weinand as the company’s new Executive Chair. “We are excited to welcome...
Replimune: Interesting Developer Of Oncolytic Immunotherapies
Replimune is developing a handful of oncolytic immunotherapies therapies targeting cancers. The company has nearly half a billion dollars in cash.
2 Biotech Stocks That Could Have Tripled Your Money This Year
One has a better chance to keep climbing than the other does.
Source: https://incomestatements.info
Category: Stock Reports